The activity of wild-type PTEN was found to be suppressed in breast and prostate cancer cells that express high levels of p110δ suggesting that the elevated expression of p110δ might provide these cells with a competitive advantage to keep their wild-type PTEN inactive (Tzenaki et al., 2012). Here, PIK3CD is linked to prostate carcinoma.